| Name | Title | Contact Details |
|---|
Enara Health is building a data-driven platform and network to scale obesity treatment. Based in San Mateo, Calif., and operating since March 2015, Enara Health offers unique hybrid digital and in-person weight loss programs based on precision medicine. By combining mobile technology with health care visits and providing patients with personalized physician-driven medical weight loss programs, Enara Health routinely helps patients lose—and keep off—more than 15% of their baseline weight, which is far greater than the results seen with other m-health interventions.
Gympass is a complete corporate wellbeing platform that ignites every journey to feel good. We`re reinventing wellbeing, making it engaging and accessible. Worldwide companies rely on Gympass` unmatched variety, convenience, and flexibility to support their employees` health and happiness. We partner with best in class wellbeing providers in multiple markets across North America, Latin America, and Europe. With over 50,000 fitness partners, 1,300 on demand classes, 2,000 hours of meditation, 1,000 healthy recipes, weekly 1:1 therapy sessions, and hundreds of personal trainers, Gympass supports every wellbeing journey.
ConcertoCare is one of the nation`s leading risk-based health care companies focused on providing integrated care for seniors where they are best served: in their homes. ConcertoCare`s programs are designed for seniors with the same core, in-home care model and composed collaboratively with patients. The ConcertoCare model improves overall health quality and outcomes with a proven track record of reducing hospital admits by 47%, readmits by 40% and ER visits by 16% while achieving an increase of 38% in annual wellness visits for the most vulnerable patient populations in the U.S., benefiting patients, payers and provider networks alike. The programs are supported by a combination of in-home medical, behavioral and social services and enhanced via advanced proprietary technologies.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Quantum Group is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Quantum Group is based in Wellington, FL. You can find more information on Quantum Group at www.quantummd.com